Drug Type Bispecific T-cell Engager (BiTE) |
Synonyms Trop2/CD3 bispecific antibody (Arbele) |
Target |
Action stimulants, inhibitors |
Mechanism CD3 stimulants(T cell surface glycoprotein CD3 stimulants), Trop-2 inhibitors(Tumor-associated calcium signal transducer 2 inhibitors) |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Gastrointestinal Neoplasms | Phase 1 | - | - | |
Colorectal Cancer | Preclinical | China | 31 May 2023 | |
Pancreatic Cancer | Preclinical | China | 31 May 2023 | |
Stomach Cancer | Preclinical | China | 31 May 2023 |